You nominated and our expert judging panels deliberated – and now, we proudly showcase this diversity of talent in The Pathologist’s 2020 Power List.
David Rimm continues the conversation about the best assay for atezolizumab after a recent response to his original article
Allen M. Gown
Emina Torlakovic and Allen Gown share their disagreements with David Rimm’s comments about an FDA-approved PD-L1 assay for atezolizumab
Not every assay that trials well is practical for implementation in daily practice. How can we tell which ones are, and whose responsibility is it?
A response to David Rimm’s letter that supports the role of PD-L1 testing in improving outcomes for cancer patients.
David L. Rimm
David Rimm challenges the sensitivity and reproducibility of a new assay for PD-L1 detection.
Liquid biopsy can help us appropriately treat patients with anti-PD-L1 immunotherapies, and ddPCR enables ongoing monitoring and adjustment of treatment
An efficient alternative to pap-HPV tests could lie with ddPCR and a ccfDNA assay
Antonia R. Sepulveda
New collaborative guidelines for molecular biomarker testing in colorectal cancer
An examination of domain-specific companion diagnostic testing
An industry pathologist’s perspective on developing a companion diagnostic
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.